Asplenia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Template) |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asplenia}} | {{Asplenia}} | ||
{{CMG}} {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | |||
There are no established measures for the secondary prevention of [disease name]. | |||
OR | |||
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
There are no established measures for the secondary prevention of [disease name]. | |||
OR | |||
Effective measures for the secondary prevention of [disease name] include: | |||
*[Strategy 1] | |||
*[Strategy 2] | |||
*[Strategy 3] | |||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Immunology]] | [[Category:Immunology]] | ||
Revision as of 02:18, 30 June 2020
Asplenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Asplenia secondary prevention On the Web |
American Roentgen Ray Society Images of Asplenia secondary prevention |
Risk calculators and risk factors for Asplenia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]